| __timestamp | Dyne Therapeutics, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 17293000 |
| Thursday, January 1, 2015 | 2028000000 | 26470000 |
| Friday, January 1, 2016 | 2281000000 | 28307000 |
| Sunday, January 1, 2017 | 2932000000 | 30354000 |
| Monday, January 1, 2018 | 24000 | 32160000 |
| Tuesday, January 1, 2019 | 271000 | 37571000 |
| Wednesday, January 1, 2020 | 700000 | 39951000 |
| Friday, January 1, 2021 | 1088000 | 50159000 |
| Saturday, January 1, 2022 | 3345000 | 54577000 |
| Sunday, January 1, 2023 | 2461000 | 61940000 |
Unleashing insights
In the dynamic world of biotechnology, understanding cost structures is crucial. Vericel Corporation and Dyne Therapeutics, Inc. offer a fascinating comparison. From 2014 to 2023, Vericel's cost of revenue grew steadily, peaking at approximately $61.9 million in 2023, marking a 258% increase from 2014. In contrast, Dyne Therapeutics experienced a volatile journey. Starting with a staggering $1.145 billion in 2014, their costs plummeted to a mere $2.46 million by 2023, a dramatic 99.8% decrease. This stark contrast highlights differing business strategies and market conditions. Vericel's consistent growth suggests a stable expansion, while Dyne's fluctuations may reflect strategic pivots or market challenges. Such insights are invaluable for investors and industry analysts seeking to understand the financial health and strategic direction of these companies.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Vericel Corporation
Cost of Revenue: Key Insights for AbbVie Inc. and Vericel Corporation
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Vericel Corporation
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost of Revenue Comparison: BeiGene, Ltd. vs Vericel Corporation
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Vericel Corporation's Expenses
Cost of Revenue Trends: Catalent, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Vericel Corporation's Expenses
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated